Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.47 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 6/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.46 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10594234 | 1.00 | LPAR5 (0.50) | LPAR5SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL6535665 | 0.85 | LPAR5 (0.49) | LPAR5SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL10594311 | 0.81 | PLA2G2C (0.50) | SMPD1FDPSGGPS1 | |
| SCHEMBL11325815 | 0.78 | SMPD1 (0.47) | SMPD1LPAR3LPAR1LPAR2FDPS | |
| Phosphorylethanolamine SCHEMBL3824970 | 0.78 | LPAR3 (0.45) | LPAR5SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL4752181 | 0.75 | ENPP2 (0.56) | LPAR5LPAR3LPAR1LPAR2LPAR6 | |
| SCHEMBL10594358 | 0.75 | LMNA (0.58) | — | |
| SCHEMBL3953269 | 0.75 | LMNA (0.58) | — | |
| Dimethylamine SCHEMBL10482623 | 0.74 | SMPD1 (0.46) | LPAR5SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL28480885 | 0.72 | LPAR5 (0.65) | LPAR5SMPD1LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563324-A1 | COSMETIC COMPOSITION CONTAINING OLIGOPEPTIDES | Cognis IP Management GmbH (DE) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134568-A1 | COSMETIC COMPOSITION CONTAINING OLIGOPEPTIDES | COGNIS IP MANAGEMENT GMBH (DE) | 2011-11-03 | — | — | WO | disclosed |
| EP-1425020-A4 | METHODS AND COMPOSITIONS FOR TREATING APOPTOSIS ASSOCIATED DISORDERS | TATTON TECHNOLOGIES LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040127468-A1 | Methods and compositions for treating apoptosis associated disorders | TATTON WILLIAM GEORGE (CA) | 2004-07-01 | — | — | US | disclosed |
| EP-1425020-A1 | METHODS AND COMPOSITIONS FOR TREATING APOPTOSIS ASSOCIATED DISORDERS | Tatton Technologies, LLC. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003015794-A1 | METHODS AND COMPOSITIONS FOR TREATING APOPTOSIS ASSOCIATED DISORDERS | TATTON TECHNOLOGIES, LLC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127468-A1 | Methods and compositions for treating apoptosis associated disorders | BAX, BCL2, CASP3 | LPAR5 338/4885SMPD1 72/4885LPAR3 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.